BR0111729A - 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais - Google Patents

1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais

Info

Publication number
BR0111729A
BR0111729A BR0111729-7A BR0111729A BR0111729A BR 0111729 A BR0111729 A BR 0111729A BR 0111729 A BR0111729 A BR 0111729A BR 0111729 A BR0111729 A BR 0111729A
Authority
BR
Brazil
Prior art keywords
dihydro
oxo
aryl
antiviral agents
quinolinecarboxamides
Prior art date
Application number
BR0111729-7A
Other languages
English (en)
Inventor
Mark E Schnute
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0111729A publication Critical patent/BR0111729A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"1-ARIL-4-OXO-1,4-DIHIDRO-3-QUINOLINACARBOXAMIDAS COMO AGENTES ANTIVIRAIS". A presente invenção fornece compostos de fórmula (I) que são úteis como agentes antivirais, em particular, como agente contra virus da família herpes.
BR0111729-7A 2000-06-16 2001-06-05 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais BR0111729A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21220200P 2000-06-16 2000-06-16
US27213601P 2001-02-28 2001-02-28
PCT/US2001/016481 WO2001098275A2 (en) 2000-06-16 2001-06-05 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Publications (1)

Publication Number Publication Date
BR0111729A true BR0111729A (pt) 2003-07-29

Family

ID=26906879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111729-7A BR0111729A (pt) 2000-06-16 2001-06-05 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais

Country Status (13)

Country Link
US (2) US6653307B2 (pt)
EP (1) EP1292575A2 (pt)
JP (1) JP2004501138A (pt)
KR (1) KR20030062235A (pt)
CN (1) CN1432001A (pt)
AR (1) AR030698A1 (pt)
AU (2) AU2001268075B2 (pt)
BR (1) BR0111729A (pt)
CA (1) CA2410452A1 (pt)
MX (1) MXPA02012493A (pt)
NZ (1) NZ523170A (pt)
PE (1) PE20011349A1 (pt)
WO (1) WO2001098275A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046115A1 (ja) 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
WO2005028478A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
KR20080095859A (ko) * 2006-01-23 2008-10-29 노파르티스 아게 고체 형태의 피롤로피리미딘 유도체 및 항종양제로서의그의 용도
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
IN2014CN00532A (pt) 2006-03-06 2015-04-03 Japan Tobacco Inc
KR101023635B1 (ko) 2006-03-06 2011-03-22 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 제조 방법
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
US10495175B2 (en) * 2017-08-08 2019-12-03 Ford Global Technologies, Llc Composite materials having embedded metal ropes for increased damping capacity and methods of manufacturing same
CN108892639B (zh) * 2018-08-13 2021-05-14 云南民族大学 一种高效环保制备喹诺酮类化合物的方法
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
CN119613333A (zh) * 2024-12-05 2025-03-14 湖北大学 一类喹诺酮类化合物及其抗病毒应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1191443A (en) 1968-02-23 1970-05-13 Warner Lambert Pharmaceutical Quinoline Derivatives
US4786664A (en) 1987-03-26 1988-11-22 General Electric Company Compatible polyphenylene ether-linear polyester blends having improved coefficient of thermal expansion
DE3811341A1 (de) 1987-10-09 1989-04-27 Bayer Ag In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
US4939290A (en) 1988-11-23 1990-07-03 Pfizer Inc. Benzoic acid derivatives
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
DE69115692T2 (de) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermisch übertragbare fluoreszierende Verbindungen
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
US5622967A (en) 1993-04-26 1997-04-22 Sterling Winthrop, Inc. Quinolone carboxamide Calpain inhibitors
FI972194A7 (fi) 1994-11-24 1997-05-22 Basilea Pharmaceutica Ag Uusia bentsyylipyrimidiinejä
PT841929E (pt) 1995-08-02 2003-09-30 Darwin Discovery Ltd Quinolonas e sua utilizacao terapeutica
ES2211965T3 (es) 1995-08-02 2004-07-16 Darwin Discovery Limited Quinolonas y su utilizacion terapeutica.
WO1997040846A1 (en) 1996-04-30 1997-11-06 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
EP0945435B1 (en) 1996-11-28 2003-08-13 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
RU2220960C2 (ru) 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе
HUP0300326A3 (en) * 2000-03-21 2003-09-29 Upjohn Co 4-oxo-1,4-dihydro-3-cinnolinecarboxamides of antiviral effect their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1292575A2 (en) 2003-03-19
WO2001098275A3 (en) 2002-07-04
AU6807501A (en) 2002-01-02
AR030698A1 (es) 2003-09-03
WO2001098275A2 (en) 2001-12-27
JP2004501138A (ja) 2004-01-15
NZ523170A (en) 2004-10-29
CN1432001A (zh) 2003-07-23
KR20030062235A (ko) 2003-07-23
CA2410452A1 (en) 2001-12-27
MXPA02012493A (es) 2003-04-25
AU2001268075B2 (en) 2005-08-18
US6653307B2 (en) 2003-11-25
US20040024209A1 (en) 2004-02-05
US20020103220A1 (en) 2002-08-01
PE20011349A1 (es) 2002-01-19

Similar Documents

Publication Publication Date Title
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
GB0011203D0 (en) Chemical compounds
DK1200418T3 (da) Nematodicide trifluorbutener
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
BR0114252A (pt) Derivados de nitrosodifenilamina
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
MY128458A (en) Antiviral azaindole derivatives
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
BR0305259A (pt) Inibidores de hcv ns5b polimerase
BR0109165A (pt) Método de tratamento de pólipos colÈnicos
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
DE69811062D1 (de) Polyaromatische antivirale zusammensetzungen
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR0210594A (pt) (beta)-d ou (beta)-l-3-halonucleosìdeo
MXPA02012493A (es) 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
ES2243579T3 (es) Derivados de pirazolopirideno.
MY133507A (en) New peroxy-carboxylic acid and aqueous compositions thereof
MY117789A (en) Pyrroloquinolones as antiviral agents
MY137766A (en) Exemestane as chemopreventing agent
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
BR0215016A (pt) Piridoquinoxalinas antivirìcas
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.